Health Resources and Services Administration (HRSA) has run the 340B Drug Pricing Program for over 30 years, until now. This month, reports have indicated that HHS leadership intends to move 340B oversight from HRSA to the Centers for Medicare and Medicaid Services (CMS) by the end of September 2026. Neither agency has publicly confirmed the move, but the signals have been building for more than a year.
At a glance:
- The proposal has survived three federal budget cycles.
- Industry reporting points to a late-September 2026 timeline.
- CMS has already built much of the regulatory groundwork.
- Reimbursement pressure is building alongside the transfer.
- Core program infrastructure would move.
- Experts expect tighter scrutiny, though views differ on the net effect.
- Litigation risk remains the biggest variable in the timeline.
- Rules identifying which Medicare Part D claims are subject to 340B pricing, with CMS projecting that 10 to 35% of total Part D claims will fall under this category
- A voluntary 340B claims data repository that providers are strongly encouraged to join
- Eligibility checks and annual recertifications
- Audits and technical assistance to covered entities
- The Office of Pharmacy Affairs Information System (OPAIS) that underpins 340B registration and pricing data
1. The proposal has survived three consecutive federal budget cycles
This move doesn’t come out of the blue. The administration first proposed shifting 340B to CMS in its FY 2026 Discretionary Budget Request. The FY 2027 budget request carried the same proposal forward, adding $8.3 million earmarked for the reorganization.
Why it matters: A plan that survives three budget cycles reflects deliberate strategic direction.
2. Industry reporting now points to a September timeline
Multiple sources report that leadership expects to complete the transfer by the end of September 2026. A separate industry publication corroborated this timeline independently, citing a source familiar with the plans.
Why it matters: Neither HHS, HRSA, nor CMS has officially confirmed this.
3. CMS has already built much of the regulatory groundwork
CMS has spent the past year assembling infrastructure a 340B takeover would require:
Why it matters: This kind of encouragement often becomes a requirement once an agency gains full jurisdiction over a program.
4. Reimbursement pressure is building alongside the transfer
CMS has already proposed cutting Medicare reimbursement for 340B-acquired drugs twice. The CY 2027 Hospital Outpatient Prospective Payment System proposal would reduce payment for most 340B drugs from average sales price plus 6% to average sales price minus 33.4%.
Why it matters: Evaluate the agency transfer and the reimbursement proposal together. Together, they could compound financial pressure on 340B-dependent providers.
5. The transfer would move core program infrastructure
A shift of this scale reaches the operational core of 340B, including:
- Eligibility checks and annual recertifications
- Audits and technical assistance to covered entities
- The Office of Pharmacy Affairs Information System (OPAIS) that underpins 340B registration and pricing data
Why it matters: That system sits at the center of daily 340B operations for hospitals, health centers, and TPAs. Any migration carries real implications for data continuity during the handoff.
6. CMS brings a different oversight model than HRSA
HRSA audits center on documentation. CMS oversight typically relies on structured data validation instead, so covered entities built around narrative compliance files may need to invest in claims-level data infrastructure to keep pace.
Why it matters: A documentation-based audit model and a data-validation-based audit model demand different preparation. Organizations should not assume today's compliance files will satisfy tomorrow's audit standard.
7. Litigation risk remains the biggest variable in the timeline
HHS Secretary Kennedy previously declined to comment on the shift's timing, citing a court order related to the department's broader reorganization plans. Litigation over HHS restructuring authority has already delayed related HHS initiatives once this year.
Why it matters: Build flexibility into 2027 compliance planning rather than anchoring to a single expected transfer date.
What This Means for Your Organization
CMS operates at a different scale than HRSA, with more resources to devote to enforcement, and it will likely expect the same kind of transparency it already requires elsewhere in Medicare. Covered entities should expect closer scrutiny of their claims data, less tolerance for documentation gaps, and a compliance bar that keeps rising regardless of when the transfer becomes official.